Single-Dose Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Apixaban in Pediatric Subjects at Risk for a Venous or Arterial Thrombotic Disorder
Phase of Trial: Phase I
Latest Information Update: 20 Nov 2017
At a glance
- Drugs Apixaban (Primary)
- Indications Thromboembolism
- Focus Pharmacokinetics
- Sponsors Bristol-Myers Squibb
- 10 Nov 2017 Planned End Date changed from 30 Oct 2017 to 30 Jan 2018.
- 10 Nov 2017 Planned primary completion date changed from 29 Oct 2017 to 29 Jan 2018.
- 12 Apr 2016 Planned number of patients changed from 40 to 44.